This care card's answer
The label does not answer the care question.
The U.S. medicine regulator, the Food and Drug Administration (FDA), had issued warnings about research-labelled products advertised for use by people as of September 26, 2026.
FDA says those products have unknown quality and could harm people.
Bring the exact name to a clinical conversation.
Write down the ingredient you were considering and the health question behind it. Discuss that question with a licensed clinician through telehealth or an in-person visit.
Ask what reviewed treatment options exist for the problem you want help with. A product page is not an assessment of your health.
Availability does not settle approval.
Retatrutide and cagrilintide are peptide names used in weight-loss product offers. As of September 26, 2026, FDA says neither has an approved drug product and neither may be made to order under federal law.
Ask the doctor about approved choices for the health problem you want help with.
Take this to the conversation
What approved care options address my health question, rather than this product's advertising?
Ask for the answer in plain words. Keep it with your visit notes.
Notes behind this answer
- FDA: research-labelled weight-loss products
Describes unknown quality and the status of retatrutide and cagrilintide.
- U.S. Code: what makes a product a drug
Read why a promise to treat disease can make a product a drug under U.S. law.
- Federal rule: evidence of intended use
Explains how a seller's words and the way a product is sold can show what it is meant to do.